Efficacy and safety of PDE5 inhibitors in middle-aged and old patients with and without hypogonadism

References

• Corona G, Cucinotta D, Di Lorenzo G, et al. The Italian Society of Andrology and Sexual Medicine (SIAMS), along with ten other Italian scientific societies, guidelines on the diagnosis and management of erectile dysfunction. J Endocrinol Invest. 2023;46(6):1241–1274. doi: 10.1007/s40618-023-02015-5.
   PubMed Web of Science ®Google Scholar
• Cellerino A, Jannini EA. Male reproductive physiology as a sexually selected handicap? Erectile dysfunction is correlated with general health and health prognosis and may have evolved as a marker of poor phenotypic quality. Med Hypotheses. 2005;65(1):179–184. doi: 10.1016/j.mehy.2004.10.020.
   PubMed Web of Science ®Google Scholar
• Kessler A, Sollie S, Challacombe B, et al. The global prevalence of erectile dysfunction: a review. BJU Int. 2019;124(4):587–599. doi: 10.1111/bju.14813.
   PubMed Web of Science ®Google Scholar
• Eardley I. The incidence, prevalence, and natural history of erectile dysfunction. Sex Med Rev. 2013;1(1):3–16. doi: 10.1002/smrj.2.
   PubMedGoogle Scholar
• Shiri R, Koskimäki J, Hakama M, et al. Prevalence and severity of erectile dysfunction in 50 to 75-year-old Finnish men. J Urol. 2003;170(6 Pt 1):2342–2344. doi: 10.1097/01.ju.0000090963.88752.84.
   PubMed Web of Science ®Google Scholar
• Pellegrino F, Sjoberg DD, Tin AL, et al. Relationship between age, comorbidity, and the prevalence of erectile dysfunction. Eur Urol Focus. 2023;9(1):162–167. doi: 10.1016/j.euf.2022.08.006.
   PubMedGoogle Scholar
• Shamloul R, Ghanem H. Erectile dysfunction. Lancet. 2013;381(9861):153–165. doi: 10.1016/S0140-6736(12)60520-0.
   PubMed Web of Science ®Google Scholar
• Khera M, Goldstein I. Erectile dysfunction. BMJ Clin Evid. 2011;2011:1803. PMID: 21711956; PMCID: PMC3217797.
   PubMedGoogle Scholar
• Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151(1):54–61. doi: 10.1016/s0022-5347(17)34871-1.
   PubMed Web of Science ®Google Scholar
• Ansong KS, Lewis C, Jenkins P, et al. Epidemiology of erectile dysfunction: a community-based study in rural New York state. Ann Epidemiol. 2000;10(5):293–296. doi: 10.1016/s1047-2797(00)00050-8.
   PubMed Web of Science ®Google Scholar
• Basaria S. Male hypogonadism. Lancet. 2014;383(9924):1250–1263. doi: 10.1016/S0140-6736(13)61126-5.
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Late-onset hypogonadism: a concept comes of age. Andrology. 2020;8(6):1506–1511. doi: 10.1111/andr.12719.
   PubMed Web of Science ®Google Scholar
• Liu YJ, Shen XB, Yu N, et al. Prevalence of late-onset hypogonadism among Middle-aged and elderly males in China: results from a national survey. Asian J Androl. 2021;23(2):170–177. doi: 10.4103/aja.aja_59_20.
   PubMed Web of Science ®Google Scholar
• Wu FC, Tajar A, Beynon JM, et al. Identification of late-onset hypogonadism in middle-aged and elderly men. N Engl J Med. 2010;363(2):123–135. doi: 10.1056/NEJMoa0911101.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Esche GR, Kupelian V, et al. Prevalence of symptomatic androgen deficiency in men. J Clin Endocrinol Metab. 2007;92(11):4241–4247. doi: 10.1210/jc.2007-1245.
   PubMed Web of Science ®Google Scholar
• Miner MM, Seftel AD. Testosterone and ageing: what have we learned since the institute of medicine report and what lies ahead. Int J Clin Pract. 2007;61(4):622–632. doi: 10.1111/j.1742-1241.2007.01317.x.
   PubMed Web of Science ®Google Scholar
• Mulligan T, Frick MF, Zuraw QC, et al. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract. 2006;60(7):762–769. doi: 10.1111/j.1742-1241.2006.00992.x.
   PubMed Web of Science ®Google Scholar
• Liu ZY, Zhou RY, Lu X, et al. Identification of late-onset hypogonadism in middle-aged and elderly men from a community of China. Asian J Androl. 2016;18(5):747–753. doi: 10.4103/1008-682X.160883.
   PubMed Web of Science ®Google Scholar
• Harman SM, Metter EJ, Tobin JD, et al. Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore longitudinal study of aging. J Clin Endocrinol Metab. 2001;86(2):724–731. doi: 10.1210/jcem.86.2.7219.
   PubMed Web of Science ®Google Scholar
• Liu CC, Wu WJ, Lee YC, et al. The prevalence of and risk factors for androgen deficiency in aging Taiwanese men. J Sex Med. 2009;6(4):936–946. doi: 10.1111/j.1743-6109.2008.01171.x.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Tarocchi M, et al. How to define hypogonadism? Results from a population of men consulting for sexual dysfunction. J Endocrinol Invest. 2016;39(4):473–484. doi: 10.1007/s40618-015-0425-1.
   PubMed Web of Science ®Google Scholar
• Corona G, Maggi M. The role of testosterone in male sexual function. Rev Endocr Metab Disord. 2022;23(6):1159–1172. doi: 10.1007/s11154-022-09748-3.
   PubMed Web of Science ®Google Scholar
• Buvat J, Bou Jaoudé G. Significance of hypogonadism in erectile dysfunction. World J Urol. 2006;24(6):657–667. doi: 10.1007/s00345-006-0131-x.
   PubMed Web of Science ®Google Scholar
• Hwang TI, Lin YC. The relationship between hypogonadism and erectile dysfunction. Int J Impot Res. 2008;20(3):231–235. doi: 10.1038/sj.ijir.3901633.
   PubMed Web of Science ®Google Scholar
• Foresta C, Caretta N, Garolla A, et al. Erectile function in elderly: role of androgens. J Endocrinol Invest. 2003;26(3 Suppl):77–81.
   PubMedGoogle Scholar
• Grossmann M, Ng Tang Fui M, Cheung AS. Late-onset hypogonadism: metabolic impact. Andrology. 2020;8(6):1519–1529. doi: 10.1111/andr.12705.
   PubMed Web of Science ®Google Scholar
• Sansone A, Mollaioli D, Ciocca G, et al. Sexual dysfunction in men and women with diabetes: a reflection of their complications. Curr Diabetes Rev. 2022;18(1):e030821192147.
   PubMed Web of Science ®Google Scholar
• Jannini EA, Screponi E, Carosa E, et al. Lack of sexual activity from erectile dysfunction is associated with a reversible reduction in serum testosterone. Int J Androl. 1999;22(6):385–392. doi: 10.1046/j.1365-2605.1999.00196.x.
   PubMedGoogle Scholar
• Buvat J, Lemaire A. Endocrine screening in 1,022 men with erectile dysfunction: clinical significance and cost-effective strategy. J Urol. 1997;158(5):1764–1767. doi: 10.1016/s0022-5347(01)64123-5.
   PubMed Web of Science ®Google Scholar
• Yuan J, Zhang R, Yang Z, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol. 2013;63(5):902–912. doi: 10.1016/j.eururo.2013.01.012.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Pili M, et al. Phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction. Curr Pharm Des. 2006;12(27):3467–3484. doi: 10.2174/138161206778343046.
   PubMed Web of Science ®Google Scholar
• Ravipati G, McClung JA, Aronow WS, et al. Type 5 phosphodiesterase inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev. 2007;15(2):76–86. doi: 10.1097/01.crd.0000233904.77128.49.
   PubMedGoogle Scholar
• Blount MA, Beasley A, Zoraghi R, et al. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol. 2004;66(1):144–152. doi: 10.1124/mol.66.1.144.
   PubMed Web of Science ®Google Scholar
• Pyrgidis N, Mykoniatis I, Haidich AB, et al. The effect of phosphodiesterase-type 5 inhibitors on erectile function: an overview of systematic reviews. Front Pharmacol. 2021;12:735708. doi: 10.3389/fphar.2021.735708.
   PubMed Web of Science ®Google Scholar
• Chen L, Staubli SE, Schneider MP, et al. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis. Eur Urol. 2015;68(4):674–680. doi: 10.1016/j.eururo.2015.03.031.
   PubMed Web of Science ®Google Scholar
• Madeira CR, Tonin FS, Fachi MM, et al. Efficacy and safety of oral phosphodiesterase 5 inhibitors for erectile dysfunction: a network meta-analysis and multicriteria decision analysis. World J Urol. 2021;39(3):953–962. doi: 10.1007/s00345-020-03233-9.
   PubMed Web of Science ®Google Scholar
• McMahon CN, Smith CJ, Shabsigh R. Treating erectile dysfunction when PDE5 inhibitors fail. BMJ. 2006;332(7541):589–592. doi: 10.1136/bmj.332.7541.589.
   PubMedGoogle Scholar
• Zhu J, Zhang W, Ou N, et al. Do testosterone supplements enhance response to phosphodiesterase 5 inhibitors in men with erectile dysfunction and hypogonadism: a systematic review and meta-analysis. Transl Androl Urol. 2020;9(2):591–600. doi: 10.21037/tau.2020.01.13.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Buvat J, Corona G, et al. A critical analysis of the role of testosterone in erectile function: from pathophysiology to treatment–a systematic review. Eur Urol. 2014;65(1):99–112. doi: 10.1016/j.eururo.2013.08.048.
   PubMed Web of Science ®Google Scholar
• Seftel AD. Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol. 2003;169(6):1999–2007. doi: 10.1097/01.ju.0000067820.86347.95.
   PubMed Web of Science ®Google Scholar
• McCullough AR, Barada JH, Fawzy A, et al. Achieving treatment optimization with sildenafil citrate (viagra) in patients with erectile dysfunction. Urology. 2002;60(2 Suppl 2):28–38. doi: 10.1016/s0090-4295(02)01688-6.
   PubMedGoogle Scholar
• Mollaioli D, Ciocca G, Limoncin E, et al. Lifestyles and sexuality in men and women: the gender perspective in sexual medicine. Reprod Biol Endocrinol. 2020;18(1):10. doi: 10.1186/s12958-019-0557-9.
   PubMed Web of Science ®Google Scholar
• Peugh J, Belenko S. Alcohol, drugs and sexual function: a review. J Psychoactive Drugs. 2001;33(3):223–232. doi: 10.1080/02791072.2001.10400569.
   PubMed Web of Science ®Google Scholar
• Cao S, Yin X, Wang Y, et al. Smoking and risk of erectile dysfunction: systematic review of observational studies with meta-analysis. PLOS One. 2013;8(4):e60443. doi: 10.1371/journal.pone.0060443.
   PubMed Web of Science ®Google Scholar
• Siasos G, Tsigkou V, Kokkou E, et al. Smoking and atherosclerosis: mechanisms of disease and new therapeutic approaches. Curr Med Chem. 2014;21(34):3936–3948. doi: 10.2174/092986732134141015161539.
   PubMed Web of Science ®Google Scholar
• Corona G, Sansone A, Pallotti F, et al. People smoke for nicotine, but lose sexual and reproductive health for tar: a narrative review on the effect of cigarette smoking on male sexuality and reproduction. J Endocrinol Invest. 2020;43(10):1391–1408. doi: 10.1007/s40618-020-01257-x.
   PubMed Web of Science ®Google Scholar
• Pourmand G, Alidaee MR, Rasuli S, et al. Do cigarette smokers with erectile dysfunction benefit from stopping?: A prospective study. BJU Int. 2004;94(9):1310–1313. doi: 10.1111/j.1464-410X.2004.05162.x.
   PubMed Web of Science ®Google Scholar
• Sansone A, Limoncin E, Colonnello E, et al. Harm reduction in sexual medicine. Sex Med Rev. 2022;10(1):3–22. doi: 10.1016/j.sxmr.2021.01.005.
   PubMed Web of Science ®Google Scholar
• Baumhäkel M, Schlimmer N, Kratz M, et al. Cardiovascular risk, drugs and erectile function–a systematic analysis. Int J Clin Pract. 2011;65(3):289–298. doi: 10.1111/j.1742-1241.2010.02563.x.
   PubMed Web of Science ®Google Scholar
• Do C, Huyghe E, Lapeyre-Mestre M, et al. Statins and erectile dysfunction: results of a case/non-case study using the French pharmacovigilance system database. Drug Saf. 2009;32(7):591–597. doi: 10.2165/00002018-200932070-00005.
   PubMed Web of Science ®Google Scholar
• Trinchieri M, Trinchieri M, Perletti G, et al. Erectile and ejaculatory dysfunction associated with use of psychotropic drugs: a systematic review. J Sex Med. 2021;18(8):1354–1363. doi: 10.1016/j.jsxm.2021.05.016.
   PubMed Web of Science ®Google Scholar
• Valeiro C, Matos C, Scholl J, et al. Drug-Induced sexual dysfunction: an analysis of reports to a national pharmacovigilance database. Drug Saf. 2022;45(6):639–650. doi: 10.1007/s40264-022-01174-3.
   PubMed Web of Science ®Google Scholar
• Gordijn R, Teichert M, Nicolai M, et al. Adverse drug reactions on sexual functioning: a systematic overview. Drug Discov Today. 2019;24(3):890–897. doi: 10.1016/j.drudis.2019.01.012.
   PubMed Web of Science ®Google Scholar
• Razdan S, Greer AB, Patel A, et al. Effect of prescription medications on erectile dysfunction. Postgrad Med J. 2018;94(1109):171–178. doi: 10.1136/postgradmedj-2017-135233.
   PubMed Web of Science ®Google Scholar
• Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev. 1999;18(1):5–24.
   PubMedGoogle Scholar
• Manolis A, Doumas M. Antihypertensive treatment and sexual dysfunction. Curr Hypertens Rep. 2012;14(4):285–292. doi: 10.1007/s11906-012-0276-5.
   PubMed Web of Science ®Google Scholar
• Bala A, Nguyen H, Hellstrom W. Post-SSRI sexual dysfunction: a literature review. Sex Med Rev. 2018;6(1):29–34. doi: 10.1016/j.sxmr.2017.07.002.
   PubMed Web of Science ®Google Scholar
• Lebret T, Rouanne M, Hublarov O, et al. Efficacy of triptorelin pamoate 11.25 mg administered subcutaneously for achieving medical castration levels of testosterone in patients with locally advanced or metastatic prostate cancer. Ther Adv Urol. 2015;7(3):125–134. doi: 10.1177/1756287215577329.
   PubMedGoogle Scholar
• Mostafa T, Alghobary M. Substance abuse and male sexual dysfunction: what lies beneath. Sex Med Rev. 2023;11(4):395–411. doi: 10.1093/sxmrev/qead011.
   PubMed Web of Science ®Google Scholar
• Defeudis G, Mazzilli R, Tenuta M, et al. Erectile dysfunction and diabetes: a melting pot of circumstances and treatments. Diabetes Metab Res Rev. 2022;38(2):e3494.
   PubMed Web of Science ®Google Scholar
• Montorsi P, Ravagnani PM, Galli S, et al. The artery size hypothesis: a macrovascular link between erectile dysfunction and coronary artery disease. Am J Cardiol. 2005;96(12B):19M–23M. doi: 10.1016/j.amjcard.2005.07.006.
   PubMed Web of Science ®Google Scholar
• Corona G, Rastrelli G, Filippi S, et al. Erectile dysfunction and Central obesity: an Italian perspective. Asian J Androl. 2014;16(4):581–591. doi: 10.4103/1008-682X.126386.
   PubMed Web of Science ®Google Scholar
• Sansone A, Reisman Y, Jannini EA. Relationship between hyperuricemia with deposition and sexual dysfunction in males and females. J Endocrinol Invest. 2022;45(4):691–703. doi: 10.1007/s40618-021-01719-w.
   PubMed Web of Science ®Google Scholar
• Rendell MS, Rajfer J, Wicker PA, et al. Sildenafil for treatment of erectile dysfunction in men with diabetes: a randomized controlled trial. Sildenafil Diabetes Study Group. JAMA. 1999;281(5):421–426. doi: 10.1001/jama.281.5.421.
   PubMed Web of Science ®Google Scholar
• Sáenz de Tejada I, Anglin G, Knight JR, et al. Effects of tadalafil on erectile dysfunction in men with diabetes. Diabetes Care. 2002;25(12):2159–2164. doi: 10.2337/diacare.25.12.2159.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Young JM, Fischer J, et al. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: a multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care. 2003;26(3):777–783. doi: 10.2337/diacare.26.3.777.
   PubMed Web of Science ®Google Scholar
• Goldstein I, Jones LA, Belkoff LH, et al. Avanafil for the treatment of erectile dysfunction: a multicenter, randomized, double-blind study in men with diabetes mellitus. Mayo Clin Proc. 2012;87(9):843–852. doi: 10.1016/j.mayocp.2012.06.016.
   PubMed Web of Science ®Google Scholar
• Van Cauwenberghe J, De Block C, Vanderschueren D, et al. Effects of treatment for diabetes mellitus on testosterone concentrations: a systematic review. Andrology. 2023;11(2):225–233. doi: 10.1111/andr.13318.
   PubMed Web of Science ®Google Scholar
• Pelusi C. The effects of the new therapeutic treatments for diabetes mellitus on the male reproductive axis. Front Endocrinol. 2022;13:821113. doi: 10.3389/fendo.2022.821113.
   PubMedGoogle Scholar
• Jannini EA, Ulisse S, D'Armiento M. Thyroid hormone and male gonadal function. Endocr Rev. 1995;16(4):443–459. doi: 10.1210/edrv-16-4-443.
   PubMed Web of Science ®Google Scholar
• Shen M, Li X, Wu W, et al. Is there an association between hypothyroidism and sexual dysfunction: a systematic review and cumulative analysis. Sex Med. 2021;9(3):100345. doi: 10.1016/j.esxm.2021.100345.
   PubMed Web of Science ®Google Scholar
• Veronelli A, Masu A, Ranieri R, et al. Prevalence of erectile dysfunction in thyroid disorders: comparison with control subjects and with obese and diabetic patients. Int J Impot Res. 2006;18(1):111–114. doi: 10.1038/sj.ijir.3901364.
   PubMed Web of Science ®Google Scholar
• Gabrielson AT, Sartor RA, Hellstrom W. The impact of thyroid disease on sexual dysfunction in men and women. Sex Med Rev. 2019;7(1):57–70. doi: 10.1016/j.sxmr.2018.05.002.
   PubMed Web of Science ®Google Scholar
• Carosa E, Lenzi A, Jannini EA. Thyroid hormone receptors and ligands, tissue distribution and sexual behavior. Mol Cell Endocrinol. 2018;467:49–59. doi: 10.1016/j.mce.2017.11.006.
   PubMed Web of Science ®Google Scholar
• Siegmann EM, Müller H, Luecke C, et al. Association of depression and anxiety disorders with autoimmune thyroiditis: a systematic review and meta-analysis. JAMA Psychiatry. 2018;75(6):577–584. doi: 10.1001/jamapsychiatry.2018.0190.
   PubMed Web of Science ®Google Scholar
• Balercia G, Boscaro M, Lombardo F, et al. Sexual symptoms in endocrine diseases: psychosomatic perspectives. Psychother Psychosom. 2007;76(3):134–140. doi: 10.1159/000099840.
   PubMed Web of Science ®Google Scholar
• Carani C, Isidori AM, Granata A, et al. Multicenter study on the prevalence of sexual symptoms in male hypo- and hyperthyroid patients. J Clin Endocrinol Metab. 2005;90(12):6472–6479. doi: 10.1210/jc.2005-1135.
   PubMed Web of Science ®Google Scholar
• Krysiak R, Szkróbka W, Okopień B. The effect of l-thyroxine treatment on sexual function and depressive symptoms in men with autoimmune hypothyroidism. Pharmacol Rep. 2017;69(3):432–437. doi: 10.1016/j.pharep.2017.01.005.
   PubMed Web of Science ®Google Scholar
• Bates JN, Kohn TP, Pastuszak AW. Effect of thyroid hormone derangements on sexual function in men and women. Sex Med Rev. 2020;8(2):217–230. doi: 10.1016/j.sxmr.2018.09.005.
   PubMed Web of Science ®Google Scholar
• Krassas GE, Tziomalos K, Papadopoulou F, et al. Erectile dysfunction in patients with hyper- and hypothyroidism: how common and should we treat. J Clin Endocrinol Metab. 2008;93(5):1815–1819. doi: 10.1210/jc.2007-2259.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zheng L, Su XM, et al. Treatment of pituitary prolactinoma reverses unresponsiveness to PDE5 inhibitor therapy in men with ED and SHPRL. Asian J Androl. 2013;15(6):847–849. doi: 10.1038/aja.2013.90.
   PubMed Web of Science ®Google Scholar
• Sansone A, Romanelli F, Gianfrilli D, et al. Endocrine evaluation of erectile dysfunction. Endocrine. 2014;46(3):423–430. doi: 10.1007/s12020-014-0254-6.
   PubMed Web of Science ®Google Scholar
• NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021;398(10304):957–980.
   PubMed Web of Science ®Google Scholar
• Mittawae B, El-Nashaar AR, Fouda A, et al. Incidence of erectile dysfunction in 800 hypertensive patients: a multicenter Egyptian national study. Urology. 2006;67(3):575–578. doi: 10.1016/j.urology.2005.09.040.
   PubMed Web of Science ®Google Scholar
• Burchardt M, Burchardt T, Baer L, et al. Hypertension is associated with severe erectile dysfunction. J Urol. 2000;164(4):1188–1191. doi: 10.1016/S0022-5347(05)67138-8.
   PubMed Web of Science ®Google Scholar
• de Oliveira AA, Nunes KP. Hypertension and erectile dysfunction: breaking down the challenges. Am J Hypertens. 2021;34(2):134–142. doi: 10.1093/ajh/hpaa143.
   PubMed Web of Science ®Google Scholar
• Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294(23):2996–3002. doi: 10.1001/jama.294.23.2996.
   PubMed Web of Science ®Google Scholar
• Wang TD, Lee CK, Chia YC, et al. Hypertension and erectile dysfunction: the role of endovascular therapy in Asia. J Clin Hypertens. 2021;23(3):481–488. doi: 10.1111/jch.14123.
   Web of Science ®Google Scholar
• Costa C, Virag R. The endothelial-erectile dysfunction connection: an essential update. J Sex Med. 2009;6(9):2390–2404. doi: 10.1111/j.1743-6109.2009.01356.x.
   PubMed Web of Science ®Google Scholar
• Patel JP, Lee EH, Mena-Hurtado CI, et al. Evaluation and management of erectile dysfunction in the hypertensive patient. Curr Cardiol Rep. 2017;19(9):89. doi: 10.1007/s11886-017-0889-z.
   PubMed Web of Science ®Google Scholar
• Papatsoris AG, Korantzopoulos PG. Hypertension, antihypertensive therapy, and erectile dysfunction. Angiology. 2006;57(1):47–52. doi: 10.1177/000331970605700107.
   PubMed Web of Science ®Google Scholar
• Aranda P, Ruilope LM, Calvo C, et al. Erectile dysfunction in essential arterial hypertension and effects of sildenafil: results of a Spanish national study. Am J Hypertens. 2004;17(2):139–145. doi: 10.1016/j.amjhyper.2003.09.006.
   PubMed Web of Science ®Google Scholar
• van Ahlen H, Wahle K, Kupper W, et al. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med. 2005;2(6):856–864. doi: 10.1111/j.1743-6109.2005.00150.x.
   PubMed Web of Science ®Google Scholar
• Brindis RG, Kloner RA. Sildenafil in patients with cardiovascular disease. Am J Cardiol. 2003;92(9A):26M–36M. doi: 10.1016/s0002-9149(02)03368-4.
   PubMed Web of Science ®Google Scholar
• Vasquez EC, Gava AL, Graceli JB, et al. Novel therapeutic targets for phosphodiesterase 5 inhibitors: current state-of-the-art on systemic arterial hypertension and atherosclerosis. Curr Pharm Biotechnol. 2016;17(4):347–364.
   PubMed Web of Science ®Google Scholar
• Giannetta E, Feola T, Gianfrilli D, et al. Is chronic inhibition of phosphodiesterase type 5 cardioprotective and safe? A meta-analysis of randomized controlled trials. BMC Med. 2014;12(1):185. doi: 10.1186/s12916-014-0185-3.
   PubMedGoogle Scholar
• Hsiao W, Bertsch RA, Hung YY, et al. Tighter blood pressure control is associated with lower incidence of erectile dysfunction in hypertensive men. J Sex Med. 2019;16(3):410–417. doi: 10.1016/j.jsxm.2019.01.011.
   PubMed Web of Science ®Google Scholar
• Düsing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003;2:29–34. doi: 10.1080/08038020310021967.
   PubMedGoogle Scholar
• Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci. 2001;321(5):336–341. doi: 10.1097/00000441-200105000-00006.
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Corradi L, et al. Sexual function in hypertensive males treated with lisinopril or atenolol: a cross-over study. Am J Hypertens. 1998;11(10):1244–1247. doi: 10.1016/s0895-7061(98)00139-3.
   PubMed Web of Science ®Google Scholar
• Baumhäkel M, Schlimmer N, Böhm M, et al. Effect of irbesartan on erectile function in patients with hypertension and metabolic syndrome. Int J Impot Res. 2008;20(5):493–500. doi: 10.1038/ijir.2008.28.
   PubMed Web of Science ®Google Scholar
• Suzuki H, Tominaga T, Kumagai H, et al. Effects of first-line antihypertensive agents on sexual function and sex hormones. J Hypertens Suppl. 1988;6(4):S649–S51. doi: 10.1097/00004872-198812040-00204.
   PubMedGoogle Scholar
• Omvik P, Thaulow E, Herland OB, et al. Double-blind, parallel, comparative study on quality of life during treatment with amlodipine or enalapril in mild or moderate hypertensive patients: a multicentre study. J Hypertens. 1993;11(1):103–113. doi: 10.1097/00004872-199301000-00015.
   PubMed Web of Science ®Google Scholar
• Nunes AP, Seeger JD, Stewart A, et al. Retrospective observational real-world outcome study to evaluate safety among patients with erectile dysfunction (ED) with co-possession of tadalafil and anti-hypertensive medications (anti-HTN). J Sex Med. 2022;19(1):74–82. doi: 10.1016/j.jsxm.2021.10.012.
   PubMed Web of Science ®Google Scholar
• Ishikura F, Beppu S, Hamada T, et al. Effects of sildenafil citrate (viagra) combined with nitrate on the heart. Circulation. 2000;102(20):2516–2521. doi: 10.1161/01.cir.102.20.2516.
   PubMed Web of Science ®Google Scholar
• Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil and 2 alpha-blockers, doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172(5 Pt 1):1935–1940. doi: 10.1097/01.ju.0000142687.75577.e4.
   PubMed Web of Science ®Google Scholar
• Montague DK, Jarow JP, Broderick GA, et al. Chapter 1: the management of erectile dysfunction: an AUA update. J Urol. 2005;174(1):230–239. doi: 10.1097/01.ju.0000164463.19239.19.
   PubMed Web of Science ®Google Scholar
• Abrams P, Cardozo L, Fall M, et al. The standardisation of terminology in lower urinary tract function: report from the standardisation sub-committee of the International Continence Society. Urology. 2003;61(1):37–49. doi: 10.1016/s0090-4295(02)02243-4.
   PubMed Web of Science ®Google Scholar
• Lee CL, Kuo HC. Pathophysiology of benign prostate enlargement and lower urinary tract symptoms: current concepts. Ci Ji Yi Xue Za Zhi. 2017;29(2):79–83. doi: 10.4103/tcmj.tcmj_20_17.
   Google Scholar
• Gomes CM, Averbeck MA, Koyama M, et al. Association among lower urinary tract symptoms, erectile function, and sexual satisfaction: results from the Brazil LUTS study. Sex Med. 2020;8(1):45–56. doi: 10.1016/j.esxm.2019.09.003.
   PubMed Web of Science ®Google Scholar
• Reggio E, de Bessa J Jr., Junqueira RG, et al. Correlation between lower urinary tract symptoms and erectile dysfunction in men presenting for prostate cancer screening. Int J Impot Res. 2007;19(5):492–495. doi: 10.1038/sj.ijir.3901557.
   PubMed Web of Science ®Google Scholar
• De Nunzio C, Roehrborn CG, Andersson KE, et al. Erectile dysfunction and lower urinary tract symptoms. Eur Urol Focus. 2017;3(4–5):352–363. doi: 10.1016/j.euf.2017.11.004.
   PubMedGoogle Scholar
• Köhler TS, McVary KT. The relationship between erectile dysfunction and lower urinary tract symptoms and the role of phosphodiesterase type 5 inhibitors. Eur Urol. 2009;55(1):38–48. doi: 10.1016/j.eururo.2008.08.062.
   PubMed Web of Science ®Google Scholar
• McVary KT, Monnig W, Camps JL Jr., et al. Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol. 2007;177(3):1071–1077. doi: 10.1016/j.juro.2006.10.055.
   PubMed Web of Science ®Google Scholar
• Martínez-Salamanca JI, Carballido J, Eardley I, et al. Phosphodiesterase type 5 inhibitors in the management of non-neurogenic male lower urinary tract symptoms: critical analysis of current evidence. Eur Urol. 2011;60(3):527–535. doi: 10.1016/j.eururo.2011.05.054.
   PubMed Web of Science ®Google Scholar
• Rappaport JA, Waldman SA. The guanylate cyclase C-cGMP signaling axis opposes intestinal epithelial injury and neoplasia. Front Oncol. 2018;8:299. doi: 10.3389/fonc.2018.00299.
   PubMed Web of Science ®Google Scholar
• Mónica FZ, De Nucci G. Tadalafil for the treatment of benign prostatic hyperplasia. Expert Opin Pharmacother. 2019;20(8):929–937. doi: 10.1080/14656566.2019.1589452.
   PubMed Web of Science ®Google Scholar
• Burnett AL. Erectile dysfunction following radical prostatectomy. JAMA. 2005;293(21):2648–2653. doi: 10.1001/jama.293.21.2648.
   PubMed Web of Science ®Google Scholar
• Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J Urol. 1982;128(3):492–497. doi: 10.1016/S0022-5347(17)53012-8.
   PubMed Web of Science ®Google Scholar
• Salonia A, Burnett AL, Graefen M, et al. Prevention and management of postprostatectomy sexual dysfunctions part 2: recovery and preservation of erectile function, sexual desire, and orgasmic function. Eur Urol. 2012;62(2):273–286. doi: 10.1016/j.eururo.2012.04.047.
   PubMed Web of Science ®Google Scholar
• Rabbani F, Stapleton AM, Kattan MW, et al. Factors predicting recovery of erections after radical prostatectomy. J Urol. 2000;164(6):1929–1934. doi: 10.1016/S0022-5347(05)66921-2.
   PubMed Web of Science ®Google Scholar
• Montorsi F, Oelke M, Henneges C, et al. Exploratory decision-tree modeling of data from the randomized REACTT trial of tadalafil versus placebo to predict recovery of erectile function after bilateral nerve-sparing radical prostatectomy. Eur Urol. 2016;70(3):529–537. doi: 10.1016/j.eururo.2016.02.036.
   PubMed Web of Science ®Google Scholar
• Salter CA, Tin AL, Bernie HL, et al. Predictors of worsening erectile function in men with functional erections early after radical prostatectomy. J Sex Med. 2022;19(12):1790–1796. doi: 10.1016/j.jsxm.2022.08.193.
   PubMed Web of Science ®Google Scholar
• Wincze JP. Psychosocial aspects of ejaculatory dysfunction and male reproduction. Fertil Steril. 2015;104(5):1089–1094. doi: 10.1016/j.fertnstert.2015.07.1155.
   PubMed Web of Science ®Google Scholar
• Luca G, Parrettini S, Sansone A, et al. The inferto-sex syndrome (ISS): sexual dysfunction in fertility care setting and assisted reproduction. J Endocrinol Invest. 2021;44(10):2071–2102. doi: 10.1007/s40618-021-01581-w.
   PubMed Web of Science ®Google Scholar
• Lu KM, Lu H, Li Z. Research progress of effects of PDE5 inhibitors on sperm motility and fertilizing capacity. Journal of Shanghai Jiao Tong University (Medical Science). 2012;32(8):1010.
   Google Scholar
• Dong L, Zhang X, Yan X, et al. Effect of phosphodiesterase-5 inhibitors on the treatment of male infertility: a systematic review and meta-analysis. World J Mens Health. 2021;39(4):776–796. doi: 10.5534/wjmh.200155.
   PubMedGoogle Scholar
• Colonnello E, Ciocca G, Limoncin E, et al. Redefining a sexual medicine paradigm: subclinical premature ejaculation as a new taxonomic entity. Nat Rev Urol. 2021;18(2):115–127. doi: 10.1038/s41585-020-00417-1.
   PubMed Web of Science ®Google Scholar
• Hou G, Zhang S, Gao M, et al. A novel tool for improving the accuracy of major depressive disorder screening: a prospective study on andrology with external validation. Psychiatry Res. 2023;326:115277. doi: 10.1016/j.psychres.2023.115277.
   PubMed Web of Science ®Google Scholar
• Araujo AB, Durante R, Feldman HA, et al. The relationship between depressive symptoms and male erectile dysfunction: cross-sectional results from the Massachusetts Male Aging Study. Psychosom Med. 1998;60(4):458–465. doi: 10.1097/00006842-199807000-00011.
   PubMed Web of Science ®Google Scholar
• Zenebe Y, Akele B, W/Selassie M, et al. Prevalence and determinants of depression among old age: a systematic review and meta-analysis. Ann Gen Psychiatry. 2021;20(1):55. doi: 10.1186/s12991-021-00375-x.
   PubMed Web of Science ®Google Scholar
• Serretti A, Chiesa A. Treatment-emergent sexual dysfunction related to antidepressants: a meta-analysis. J Clin Psychopharmacol. 2009;29(3):259–266. doi: 10.1097/JCP.0b013e3181a5233f.
   PubMed Web of Science ®Google Scholar
• Jannini EA, Nappi RE. Couplepause: a new paradigm in treating sexual dysfunction during menopause and andropause. Sex Med Rev. 2018;6(3):384–395. doi: 10.1016/j.sxmr.2017.11.002.
   PubMed Web of Science ®Google Scholar
• Sansone A, Reisman Y, Meto S, et al. The role of the “anti-inflammatory” couple for the management of hyperuricemia with deposition. Sex Med. 2022;10(5):100562. doi: 10.1016/j.esxm.2022.100562.
   PubMed Web of Science ®Google Scholar
• Colonnello E, Limoncin E, Ciocca G, et al. The lost penis syndrome: a new clinical entity in sexual medicine. Sex Med Rev. 2022;10(1):113–129. doi: 10.1016/j.sxmr.2021.08.001.
   PubMed Web of Science ®Google Scholar
• Seidman SN, Roose SP, Menza MA, et al. Treatment of erectile dysfunction in men with depressive symptoms: results of a placebo-controlled trial with sildenafil citrate. Am J Psychiatry. 2001;158(10):1623–1630. doi: 10.1176/appi.ajp.158.10.1623.
   PubMed Web of Science ®Google Scholar
• Shim YS, Pae CU, Cho KJ, et al. Effects of daily low-dose treatment with phosphodiesterase type 5 inhibitor on cognition, depression, somatization and erectile function in patients with erectile dysfunction: a double-blind, placebo-controlled study. Int J Impot Res. 2014;26(2):76–80. doi: 10.1038/ijir.2013.38.
   PubMed Web of Science ®Google Scholar
• Liebenberg N, Harvey BH, Brand L, et al. Chronic treatment with the phosphodiesterase type 5 inhibitors sildenafil and tadalafil display anxiolytic effects in flinders sensitive line rats. Metab Brain Dis. 2012;27(3):337–340. doi: 10.1007/s11011-012-9284-z.
   PubMed Web of Science ®Google Scholar
• Aversa A, Duca Y, Condorelli RA, et al. Androgen deficiency and phosphodiesterase type 5 expression changes in aging male: therapeutic implications. Front Endocrinol. 2019;10:225. doi: 10.3389/fendo.2019.00225.
   PubMed Web of Science ®Google Scholar
• Morelli A, Filippi S, Mancina R, et al. Androgens regulate phosphodiesterase type 5 expression and functional activity in corpora cavernosa. Endocrinology. 2004;145(5):2253–2263. doi: 10.1210/en.2003-1699.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Rajfer J, Aversa A, et al. The evolving role of testosterone in the treatment of erectile dysfunction. Int J Clin Pract. 2006;60(9):1087–1092. doi: 10.1111/j.1742-1241.2006.01101.x.
   PubMed Web of Science ®Google Scholar
• Lin CS, Chow S, Lau A, et al. Identification and regulation of human PDE5A gene promoter. Biochem Biophys Res Commun. 2001;280(3):684–692. doi: 10.1006/bbrc.2000.4220.
   PubMed Web of Science ®Google Scholar
• Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97(18):1837–1847. doi: 10.1161/01.cir.97.18.1837.
   PubMed Web of Science ®Google Scholar
• Sansone A, Rastrelli G, Cignarelli A, et al. Effect of treatment with testosterone on endothelial function in hypogonadal men: a systematic review and meta-analysis. Int J Impot Res. 2020;32(4):379–386. doi: 10.1038/s41443-019-0163-6.
   PubMed Web of Science ®Google Scholar
• Buvat J, Montorsi F, Maggi M, et al. Hypogonadal men nonresponders to the PDE5 inhibitor tadalafil benefit from normalization of testosterone levels with a 1% hydroalcoholic testosterone gel in the treatment of erectile dysfunction (TADTEST study). J Sex Med. 2011;8(1):284–293. doi: 10.1111/j.1743-6109.2010.01956.x.
   PubMed Web of Science ®Google Scholar
• Shamloul R, Ghanem H, Fahmy I, et al. Testosterone therapy can enhance erectile function response to sildenafil in patients with PADAM: a pilot study. J Sex Med. 2005;2(4):559–564. doi: 10.1111/j.1743-6109.2005.00071.x.
   PubMed Web of Science ®Google Scholar
• Spitzer M, Basaria S, Travison TG, et al. Effect of testosterone replacement on response to sildenafil citrate in men with erectile dysfunction: a parallel, randomized trial. Ann Intern Med. 2012;157(10):681–691. doi: 10.7326/0003-4819-157-10-201211200-00004.
   PubMed Web of Science ®Google Scholar
• Narukawa T, Soh J, Kanemitsu N, et al. Efficacy of testosterone replacement therapy plus alternate-day tadalafil for patients with late-onset hypogonadism: an open-label, randomized, crossover study. Int J Urol. 2021;28(4):376–381. doi: 10.1111/iju.14468.
   PubMed Web of Science ®Google Scholar
• Hwang TI, Chen HE, Tsai TF, et al. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone. Int J Impot Res. 2006;18(4):400–404. doi: 10.1038/sj.ijir.3901446.
   PubMed Web of Science ®Google Scholar
• Ozcan L, Polat EC, Kocaaslan R, et al. Effects of taking tadalafil 5 mg once daily on erectile function and total testosterone levels in patients with metabolic syndrome. Andrologia. 2017;49(9):e12751. doi: 10.1111/and.12751.
   Web of Science ®Google Scholar
• Aversa A, Isidori AM, Spera G, et al. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol. 2003;58(5):632–638. doi: 10.1046/j.1365-2265.2003.01764.x.
   PubMed Web of Science ®Google Scholar
• Yassin AA, Saad F, Diede HE. Testosterone and erectile function in hypogonadal men unresponsive to tadalafil: results from an open-label uncontrolled study. Andrologia. 2006;38(2):61–68. doi: 10.1111/j.1439-0272.2006.00712.x.
   PubMed Web of Science ®Google Scholar
• Shabsigh R, Kaufman JM, Steidle C, et al. Randomized study of testosterone gel as adjunctive therapy to sildenafil in hypogonadal men with erectile dysfunction who do not respond to sildenafil alone. J Urol. 2008;172(2):658–663. doi: 10.1016/j.juro.2008.03.145.
   Google Scholar
• Garcia JA, Sanchez PE, Fraile C, et al. Testosterone undecanoate improves erectile dysfunction in hypogonadal men with the metabolic syndrome refractory to treatment with phosphodiesterase type 5 inhibitors alone. Andrologia. 2011;43(5):293–296. doi: 10.1111/j.1439-0272.2009.00991.x.
   PubMed Web of Science ®Google Scholar
• Jannini EA, Gravina GL, Morgentaler A, et al. Is testosterone a friend or a foe of the prostate. J Sex Med. 2011;8(4):946–955. doi: 10.1111/j.1743-6109.2011.02233.x.
   PubMed Web of Science ®Google Scholar